<code id='22F043DD15'></code><style id='22F043DD15'></style>
    • <acronym id='22F043DD15'></acronym>
      <center id='22F043DD15'><center id='22F043DD15'><tfoot id='22F043DD15'></tfoot></center><abbr id='22F043DD15'><dir id='22F043DD15'><tfoot id='22F043DD15'></tfoot><noframes id='22F043DD15'>

    • <optgroup id='22F043DD15'><strike id='22F043DD15'><sup id='22F043DD15'></sup></strike><code id='22F043DD15'></code></optgroup>
        1. <b id='22F043DD15'><label id='22F043DD15'><select id='22F043DD15'><dt id='22F043DD15'><span id='22F043DD15'></span></dt></select></label></b><u id='22F043DD15'></u>
          <i id='22F043DD15'><strike id='22F043DD15'><tt id='22F043DD15'><pre id='22F043DD15'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:1
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          FDA approves potent Eli Lilly obesity drug, Zepbound
          FDA approves potent Eli Lilly obesity drug, Zepbound

          DarronCummings/APEliLilly’sblockbusterdrugtirzepatide,soldasMounjarofortype2diabetes,hasbeenclearedt

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Excited delirium, Elijah McClain, and emergency physicians

          Theterm“exciteddelirium”hasbeenusedforyearsbylawenforcementandotherfirstresponders,includinghealthca